Spondyloarthritis
Musculoskeletal·MeSH: Axial Spondyloarthritis
Prevalence
310.0 / 100K
Incidence
7.3 / 100K/yr
8 drugs in development·7 companies·1 clinical trial
Drug Pipeline by Phase
Approved(2)
Phase 3(1)
| Drug | Company |
|---|---|
| secukinumab | Novartis AG (NVS) |
Phase 2(4)
Phase 1(1)
| Drug | Company |
|---|---|
| PN-881 | Protagonist Therapeutics, Inc (PTGX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Spondyloarthritis?
BioSniper tracks 8 drugs in development for Spondyloarthritis across 7 companies.
How many clinical trials target Spondyloarthritis?
There are 1 clinical trial targeting Spondyloarthritis tracked by BioSniper.
What is the prevalence of Spondyloarthritis?
The estimated prevalence of Spondyloarthritis is approximately 310.0 per 100,000 population.
Deep-dive into Spondyloarthritis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis